Overview

Study of Two Tramadol Contramid® OAD 300 mg Controlled-Release Tablets From Two Different Manufacturing Sites Following a 300 mg Dose in Healthy Subjects Under Fasting and Fed Conditions

Status:
Completed

Trial end date:
2006-04-01

Target enrollment:

Participant gender:

Summary

The objective of this study is to compare the rate and extent of absorption of two Tramadol Contramid® OAD 300 mg controlled-release tablets from two different manufacturing sites, administered as 1 x 300 mg controlled-release tablet under fasting conditions. The effect of food on the to-be-marketed formulation was also assessed.

Phase:

Phase 1

Details

Lead Sponsor:

Labopharm Inc.

Treatments:

Tramadol